SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 375.21 |
| Enterprise Value ($M) | 295.67 |
| Book Value ($M) | 331.56 |
| Book Value / Share | 3.11 |
| Price / Book | 1.13 |
| NCAV ($M) | 297.08 |
| NCAV / Share | 2.79 |
| Price / NCAV | 1.26 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.33 |
| Return on Assets (ROA) | -0.39 |
| Return on Equity (ROE) | -0.47 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.18 |
| Current Ratio | 17.18 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 344.29 |
| Assets | 378.78 |
| Liabilities | 47.22 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Vanguard Group Inc | |||
| 13G/A | Fmr Llc | |||
| 13G/A | Logos Global Management LP | 2.70 | -58.24 | |
| 13G/A | Bb Biotech Ag | 4.90 | 10.14 | |
| 13G/A | Biotechnology Value Fund L P | 8.40 | 28.97 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 1.00 | -64.03 | |
| 13G/A | Bain Capital Life Sciences Fund, L.P. | 5.50 | -25.89 | |
| 13G/A | Adage Capital Management, L.P. | 3.28 | ||
| 13G | BlackRock, Inc. | 7.20 | 0.00 | |
| 13G/A | Eventide Asset Management, Llc | 0.00 | -100.00 | |
| 13G/A | Venrock Healthcare Capital Partners II, L.P. | 1.20 | -80.35 | |
| 13G/A | Fairmount Funds Management LLC | 0.40 | -91.23 | |
| 13G/A | Redmile Group, LLC | 9.90 | 65.06 | |
| 13G/A | Citadel Advisors Llc | 1.40 | ||
| 13G | Point72 Asset Management, L.P. | 6.20 | ||
| 13G/A | Adage Capital Partners Gp, L.l.c. | 7.15 | 34.56 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 331,149 | 918,688 | 36.05 | |
| 399,172 | 1,012,835 | 39.41 | |
| 307,512 | 1,216,872 | 25.27 | |
| 908,880 | 2,441,975 | 37.22 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AMPH – Amphastar Pharmaceuticals, Inc. | AMRX – Amneal Pharmaceuticals, Inc. |
| ANAB – AnaptysBio, Inc. | APLS – Apellis Pharmaceuticals, Inc. |
| ARQT – Arcutis Biotherapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io